These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32727929)

  • 41. Distinction of high-grade neuroendocrine carcinoma/small cell carcinoma from conventional urothelial carcinoma of urinary bladder: an immunohistochemical approach.
    Thompson S; Cioffi-Lavina M; Chapman-Fredricks J; Gomez-Fernandez C; Fernandez-Castro G; Jorda M
    Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):395-9. PubMed ID: 21617524
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Large cell neuroendocrine [corrected] carcinoma of the uterine cervix: a clinicopathologic study of 12 cases.
    Gilks CB; Young RH; Gersell DJ; Clement PB
    Am J Surg Pathol; 1997 Aug; 21(8):905-14. PubMed ID: 9255253
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mixed small cell carcinomas of the uterine cervix: prognostic impact of focal neuroendocrine differentiation but not of Ki-67 labeling index.
    Horn LC; Hentschel B; Bilek K; Richter CE; Einenkel J; Leo C
    Ann Diagn Pathol; 2006 Jun; 10(3):140-3. PubMed ID: 16730307
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Coexistence of metastatic neuroendocrine carcinoma of the uterine cervix with human immunodeficiency virus infection.
    Balega J; Ulbright TM; Look KY
    Int J Gynecol Cancer; 2001; 11(4):334-7. PubMed ID: 11520378
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PI3K p110α inhibition sensitizes cervical cancer cells with aberrant PI3K signaling activation to PARP inhibitor BMN673.
    Cao P; Wang Y; Lv Y; Jiang N; Zhong L; Ma X; Xiao X; Ding D; Gu J; Lin L; Li S
    Oncol Rep; 2019 Nov; 42(5):2097-2107. PubMed ID: 31545455
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas.
    Yang SX; Kummar S; Steinberg SM; Murgo AJ; Gutierrez M; Rubinstein L; Nguyen D; Kaur G; Chen AP; Giranda VL; Tomaszewski JE; Doroshow JH;
    Cancer Biol Ther; 2009 Nov; 8(21):2004-9. PubMed ID: 19823047
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinicopathological characteristics and molecular abnormalities of primary grade 2 neuroendocrine tumors of the cervix.
    Zhu R; Wu H; Chen B; Pang J; Huo Z
    Diagn Pathol; 2019 Jun; 14(1):64. PubMed ID: 31228945
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors.
    Agoff SN; Lamps LW; Philip AT; Amin MB; Schmidt RA; True LD; Folpe AL
    Mod Pathol; 2000 Mar; 13(3):238-42. PubMed ID: 10757334
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
    Cook SA; Tinker AV
    BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).
    Thaker PH; Salani R; Brady WE; Lankes HA; Cohn DE; Mutch DG; Mannel RS; Bell-McGuinn KM; Di Silvestro PA; Jelovac D; Carter JS; Duan W; Resnick KE; Dizon DS; Aghajanian C; Fracasso PM
    Ann Oncol; 2017 Mar; 28(3):505-511. PubMed ID: 27998970
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy.
    Shah AP; Patel CN; Sureja DK; Sanghavi KP
    Folia Med (Plovdiv); 2018 Mar; 60(1):39-47. PubMed ID: 29668451
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Microsatellite instability, expression of hMSH2 and hMLH1 and HPV infection in cervical cancer and their clinico-pathological association.
    Chung TK; Cheung TH; Wang VW; Yu MY; Wong YF
    Gynecol Obstet Invest; 2001; 52(2):98-103. PubMed ID: 11586036
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Promyelocytic leukemia zinc finger and histone H1.5 differentially stain low- and high-grade pulmonary neuroendocrine tumors: a pilot immunohistochemical study.
    Hechtman JF; Beasley MB; Kinoshita Y; Ko HM; Hao K; Burstein DE
    Hum Pathol; 2013 Jul; 44(7):1400-5. PubMed ID: 23416030
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical implications of mismatch repair deficiency screening in patients with mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN).
    Lou L; Lv F; Wu X; Li Y; Zhang X
    Eur J Surg Oncol; 2021 Feb; 47(2):323-330. PubMed ID: 32907775
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
    Rajawat J; Shukla N; Mishra DP
    Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Small cell neuroendocrine carcinomas of the uterine cervix: a histological, immunohistochemical, and molecular genetic study.
    Ishida GM; Kato N; Hayasaka T; Saito M; Kobayashi H; Katayama Y; Sasou S; Yaegashi N; Kurachi H; Motoyama T
    Int J Gynecol Pathol; 2004 Oct; 23(4):366-72. PubMed ID: 15381906
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination Therapy with Radiation and PARP Inhibition Enhances Responsiveness to Anti-PD-1 Therapy in Colorectal Tumor Models.
    Seyedin SN; Hasibuzzaman MM; Pham V; Petronek MS; Callaghan C; Kalen AL; Mapuskar KA; Mott SL; Spitz DR; Allen BG; Caster JM
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):81-92. PubMed ID: 32036006
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    Flores Legarreta A; Salvo G; Gonzales NR; Chisholm G; Hillman RT; Frumovitz M
    J Gynecol Oncol; 2023 Jul; 34(4):e50. PubMed ID: 36807750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.